Skip to main content
Figure 3 | Molecular Neurodegeneration

Figure 3

From: Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats

Figure 3

CSF Aβ levels were increased and soluble brain Aβ levels were decreased by LXR agonists. The levels of Aβ40 and Aβ42 in the CSF and soluble brain extracts were evaluated by ELISA as described in Methods. A: Aβ40 and Aβ42 levels in the CSF of rats treated with LXR agonists in comparison to the vehicle control. B: Aβ40 levels in the DEA-soluble brain fraction of rats treated with LXR agonists in comparison to the vehicle control. * p < 0.05 compared to vehicle treated controls by ANOVA, N = 4 per group.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326